NURS FPX 4055 Assessment 4 Health Promotion Plan Presentation

Student Name

Capella University

NURS-FPX4055 Optimizing Population Health through Community Practice

Prof. Name

Date

Health Promotion Plan Presentation

Good morning, everyone. We are pleased to welcome our partners to today’s session. The focus of this session is the prevention of Human Papillomavirus (HPV) infection among adolescents and young adults aged 11–26 in Schwenksville, Pennsylvania. During this presentation, we will explore the link between HPV and cancer, the benefits of timely vaccination, and effective strategies for discussing HPV vaccination with healthcare providers and family members. The presentation aligns with the SMART goals we collaboratively developed and supports Healthy People 2030 objectives. Below is the roadmap for the session.

Presentation Roadmap

Throughout the session, participants will:

• Receive essential information on HPV, its transmission, and its connection to cancer.
• Understand the importance, safety, and efficacy of the HPV vaccine.
• Be encouraged to schedule the HPV vaccine within the next 30 days.
• Gain confidence in discussing HPV vaccination with healthcare providers and family members.
• Participate in interactive activities and discussions to reinforce learning.
• Complete a post-session quiz and survey to evaluate knowledge and confidence.

Key Information About HPV and Its Link to Cancer

HPV is one of the most prevalent viruses worldwide, transmitted primarily through sexual contact and skin-to-skin interaction. Data from Pennsylvania indicate that only 68.7% of adolescents are fully vaccinated against HPV-related cancers, with vaccination rates in rural areas like Schwenksville as low as 48.7% (PA.gov, 2025). Given the high incidence and mortality of HPV-associated cancers in these regions, raising awareness and increasing vaccine uptake is critical.

HPV is a leading cause of cervical, anal, throat, and genital cancers. High-risk strains such as HPV 16 and 18 can induce persistent infections that may progress to cancer over time (Huber et al., 2021). Early detection is challenging because infections often remain asymptomatic for years. Vaccination is the most effective method to prevent high-risk HPV infections, complemented by routine screenings to reduce cancer risk.

Question	Answer
What is HPV and how is it transmitted?	HPV is a common virus primarily spread through sexual contact and skin-to-skin interaction.
What types of cancers are linked to HPV?	HPV can lead to cervical, anal, oropharyngeal, and genital cancers, particularly from high-risk strains HPV 16 and 18.
Why is early detection important?	Many HPV infections are asymptomatic, but persistent infections increase cancer risk over time.

Benefits of Timely HPV Vaccination

Vaccinating adolescents against HPV offers multiple benefits, particularly when administered around ages 11–12, before exposure to the virus. These benefits include:

• Optimal Immune Response: Early vaccination enhances the immune system’s ability to generate a strong, long-lasting defense against HPV (Hoes et al., 2021).
• Cervical Cancer Prevention: HPV vaccination prevents the most dangerous virus strains, significantly lowering the risk of cervical cancer—the second most common cancer in women worldwide (Huber et al., 2021).
• Reduction in Other HPV-Related Cancers: Vaccination decreases the likelihood of anal, penile, and oropharyngeal cancers in both genders (Cheng et al., 2020).
• Prevention of Genital Warts: Early immunization prevents the painful and socially stigmatizing effects of genital warts.
• Community Immunity: Broad vaccination coverage reduces HPV transmission within communities, protecting even those who are unvaccinated or immunocompromised (Xu et al., 2024).

Question	Answer
When should the HPV vaccine ideally be given?	Around ages 11–12, before sexual exposure to HPV.
What are the main benefits of vaccination?	Prevents cervical and other HPV-related cancers, genital warts, and contributes to community immunity.
How does early vaccination strengthen immunity?	It generates a stronger, longer-lasting immune response before virus exposure.

Strategies for Discussing HPV Vaccination

Effective communication is essential when discussing HPV vaccination with healthcare providers and family members. Key strategies include:

1. Using Evidence-Based Facts: Share information from credible sources such as the CDC or WHO, emphasizing the vaccine’s safety and efficacy.
2. Asking Informed Questions: Encourage dialogue by asking questions like “What are the long-term benefits of the HPV vaccine?” or “How will this affect my health?” (Kassymbekova et al., 2023).
3. Addressing Common Myths: Respond to misconceptions calmly. For instance, explain that the vaccine prevents cancer and does not encourage early sexual activity.

Question	Answer
How should one prepare for conversations about HPV vaccination?	By gathering evidence-based information, asking informed questions, and addressing myths calmly.
What is a common misconception about the vaccine?	That it encourages early sexual activity; its purpose is cancer prevention.

Developed SMART Goals with the Participants

The SMART goals for today’s session were:

1. Knowledge Goal: By session’s end, 90% of participants will identify at least three key facts about HPV and its link to cancer.
2. Action Goal: At least 80% of participants will commit to scheduling the first HPV vaccine dose within 30 days.
3. Confidence Goal: 85% of participants will feel more confident discussing HPV vaccination with healthcare providers and family members.

These goals aim to empower participants with knowledge and action strategies for personal and community health.

Session Evaluation on Developed SMART Goals

The session achieved most of its SMART goals:

Goal	Outcome	Notes
Identify ≥3 HPV facts	92.5% of participants	Goal achieved; participants engaged actively in discussions.
Commit to vaccination	75% of participants	Slightly below 80% target; many teens deferred decision for family discussion.
Confidence discussing HPV	85% of participants	Goal achieved; some participants requested additional support in addressing myths.

Future Recommendations:

• Allow participants to involve family members during the session.
• Incorporate structured role-playing and myth-busting exercises.
• Consider follow-up meetings for hesitant participants.

Session Evaluation on Healthy People 2030 Objectives

The session aligned with Healthy People 2030 objectives by increasing awareness of HPV and its preventive measures. Knowledge gains were high, with 92.5% of participants learning key facts and 85% improving communication confidence (U.S. Department of Health and Human Services, n.d.).

However, vaccine commitment fell short of the 80% target, highlighting the need for extended family engagement, evidence-backed myth-busting, and follow-up support to improve adherence. Implementing these strategies can help achieve national vaccination goals and strengthen community health (Xu et al., 2024).

Conclusion

The session underscored that HPV vaccination is critical for cancer prevention and long-term health among adolescents and young adults in Schwenksville, Pennsylvania. By increasing awareness, promoting timely vaccination, and improving communication strategies, communities can achieve better health outcomes. While participants demonstrated strong knowledge gains and confidence, continued efforts—especially family engagement and myth-busting education—will further enhance HPV vaccination rates and support Healthy People 2030 objectives.

References

Cheng, L., Wang, Y., & Du, J. (2020). Human papillomavirus vaccines: An updated review. Vaccines, 8(3), 391. https://doi.org/10.3390/vaccines8030391

Hoes, J., Pasmans, H., Schurink-van ’t Klooster, T. M., van der Klis, F. R. M., Donken, R., Berkhof, J., & de Melker, H. E. (2021). Review of long-term immunogenicity following HPV vaccination: Gaps in current knowledge. Human Vaccines & Immunotherapeutics, 18(1). https://doi.org/10.1080/21645515.2021.1908059

NURS FPX 4055 Assessment 4 Health Promotion Plan Presentation

Huber, J., Mueller, A., Sailer, M., & Regidor, P.-A. (2021). Human papillomavirus persistence or clearance after infection in reproductive age. What is the status? Review of the literature and new data of a vaginal gel containing silicate dioxide, citric acid, and selenite. Women’s Health, 17, 174550652110207. https://doi.org/10.1177/17455065211020702

Kassymbekova, F., Zhetpisbayeva, I., Tcoy, E., Dyussenov, R., Davletov, K., Rommel, A., & Glushkova, N. (2023). Exploring HPV vaccine knowledge, attitudes, barriers and information sources among parents, health professionals and teachers in Kazakhstan: A mixed-methods study protocol. BMJ Open, 13(9), e074097. https://doi.org/10.1136/bmjopen-2023-074097

PA.gov. (2025). Dear VFC provider. https://www.pa.gov/content/dam/copapwp-pagov/en/health/documents/topics/documents/programs/immunizations/3.3.25%20-%202025%20HPV%20Call-to-Action%20Letter%20and%20Resources.pdf

NURS FPX 4055 Assessment 4 Health Promotion Plan Presentation

U.S. Department of Health and Human Services. (n.d.). Vaccination – Healthy People 2030. Health.gov. https://odphp.health.gov/healthypeople/objectives-and-data/browse-objectives/vaccination

Xu, M., Choi, J., Capasso, A., & DiClemente, R. (2024). Improving HPV vaccination uptake among adolescents in low-resource settings: Sociocultural and socioeconomic barriers and facilitators. Adolescent Health Medicine and Therapeutics, 15, 73–82. https://doi.org/10.2147/ahmt.s394119